BR-A-657, A Phase 1, Double-blind, Placebo-controlled, Ascending Single Oral Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Male Subjects Incorporating a Comparison of Fed/Fasted Pharmacokinetics
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Fimasartan (Primary)
- Indications Essential hypertension
- Focus Adverse reactions
- Sponsors Boryung Pharmaceutical
- 05 Sep 2014 New trial record